共 106 条
[1]
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 71 209-249
[2]
Ferlay J(2021)Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry Gastric Cancer. 24 545-566
[3]
Siegel RL(2020)Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial JAMA Oncol. 6 1571-1580
[4]
Suzuki S(2019)Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) Ann Oncol. 30 250-258
[5]
Takahashi A(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet. 398 27-40
[6]
Ishikawa T(2023)Japanese gastric cancer treatment guidelines 2021 (6th Edition) Gastric Cancer. 26 1-25
[7]
Shitara K(2022)Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up Ann Oncol. 33 1005-1020
[8]
Van Cutsem E(2022)Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw. 20 167-192
[9]
Bang YJ(2021)Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor Oncogene. 40 1393-1395
[10]
Boku N(2021)Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer Br J Cancer. 124 595-603